K. Lorizzo

Safety of everolimus plus exemestane in patients with hormone-receptor–positive, HER2–negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET)

Guy Jérusalem, Gabriella Mariani, Eva Ciruelos et al. · Annals of Oncology · 2016 · 74 citations · Full text

Medicine, Oncology, Pharmacology +17

Breast cancer in Hodgkin's disease and non-Hodgkin's lymphoma survivors

Giuseppina Sanna, K. Lorizzo, Nicole Rotmensz et al. · Annals of Oncology · 2006 · 55 citations · Full text

Medicine, Oncology, Breast Oncology +8

Preoperative versus postoperative docetaxel–cisplatin–fluorouracil (TCF) chemotherapy in locally advanced resectable gastric carcinoma: 10-year follow-up of the SAKK 43/99 phase III trial

Nicola Fazio, Roberto Biffi, Rudolf Maibach et al. · Annals of Oncology · 2015 · 48 citations · Full text

Medicine, Oncology, Surgery +8

First clinical experience of orally active epidermal growth factor receptor inhibitor combined with simplified FOLFOX6 as first‐line treatment for metastatic colorectal cancer

Maria Giulia Zampino, Elena Magni, Cristian Massacesi et al. · Cancer · 2007 · 37 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

First-line gefitinib combined with simplified FOLFOX-6 in patients with epidermal growth factor receptor-positive advanced colorectal cancer

Maria Giulia Zampino, K. Lorizzo, Cristian Massacesi et al. · Journal of Clinical Oncology · 2005 · 23 citations

Medicine, Pharmacology, Pharmacotherapy +15